March 11, 2018
1 min read
Save

Patients with Tönnis grade 1 vs grade 0 had similar improvements after arthroscopic treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS — Patients with Tönnis grade 1 who underwent arthroscopic treatment of femoroacetabular impingement and labral tears had similar durable improvements at 5-year follow-up as patients with Tönnis grade 0, according to results presented here.

“While strict surgical indications and appropriate expectations are recommended — you remember they had 30% conversion to total hip at a minimum of 5 years [which] are recommended for patients with mild osteoarthritis, which is the Tönnis grade 1 — the Tönnis grade 1 alone should not be considered a contraindication for hip arthroscopy,” Itay Perets, MD, said in his presentation at the American Academy of Orthopaedic Surgeons Annual Meeting.

Among 292 patients who underwent arthroscopic treatment of both femoroacetabular impingement and labral tear, Perets and colleagues evaluated 85 patients with Tönnis grade 1. Patients with Tönnis grade 1 had significant improvements in all patient-reported outcomes, a satisfaction rate of 8.2 and a survivorship of 70% at a minimum 5-year follow-up.

When matched with 62 patients with Tönnis grade 0, Perets noted no significant differences in group score or survivorship between the groups, as well as no significant difference in conversion to total hip.

“There is a difference in time to total hip, which is longer in the Tönnis 1,” Perets said.

He added patients with Tönnis grade 1 had higher acetabular Outerbridge grade 4. After matching both groups, results showed improvement in all patient-reported outcomes and VAS from preoperative to postoperative measures, Perets noted. – by Casey Tingle

Reference:

Domb BG, et al. Paper #536. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting; March 6-10, 2018; New Orleans.

Disclosure: Perets reports no relevant financial disclosures.